Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
21.52
-1.24 (-5.45%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Nuvectis Pharma Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Nuvectis Pharma stock has a consensus rating of "Strong Buy" and an average price target of $31.8. The average 1-year stock price forecast is 47.77% higher than the current stock price, while the lowest is $22 (+2.23%) and the highest is $39 (+81.23%).
Price Target: $31.8 (+47.77%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Nuvectis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Feb '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Reiterates $30 | Buy | Reiterates | $30 | +39.41% | Jul 24, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $39 | Buy | Reiterates | $39 | +81.23% | Jul 23, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $20 → $33 | Buy | Reiterates | $20 → $33 | +53.35% | Jul 6, 2026 |
| Lucid Capital | Lucid Capital | Buy Maintains $18 → $22 | Buy | Maintains | $18 → $22 | +2.23% | Jun 22, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a